Felicitas Pardow

Ms. Felicitas Pardow

Radboudumc, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in Cancers
Verified
Journal Article
Open access
PDF file
KPKatherine E. Pickup
Katherine E. Pickup
FPFelicitas Pardow
Felicitas Pardow
JCJosé Carbonell
José Carbonell
ALAntonios Lioutas
Antonios Lioutas
JVJosé Luis Villanueva-Cañas
José Luis Villanueva-Cañas
MBMiguel Beato
Miguel Beato
The growth of cancer cells as oncospheres in three-dimensional (3D) culture provides a robust cell model for understanding cancer progression, as well as for early drug discovery and validation. We have previously described a novel pathway in breast cancer cells, whereby ADP (Adenosine diphosphate)-ribose derived from hydrolysis of poly (ADP-Ribose) and pyrophosphate (PPi) are converted to ATP, catalysed by the enzyme NUDT5 (nucleotide diphosphate hydrolase type 5). Overexpression of the NUDT5 gene in breast and other cancer types is associated with poor prognosis, increased risk of recurrence and metastasis. In order to understand the role of NUDT5 in cancer cell growth, we performed phenotypic and global expression analysis in breast cancer cells grown as oncospheres. Comparison of two-dimensional (2D) versus 3D cancer cell cultures from different tissues of origin suggest that NUDT5 increases the aggressiveness of the disease via the modulation of several key driver genes, including ubiquitin specific peptidase 22 (USP22), RAB35B, focadhesin (FOCAD) and prostagladin E synthase (PTGES). NUDT5 functions as a master regulator of key oncogenic pathways and of genes involved in cell adhesion, cancer stem cell (CSC) maintenance and epithelial to mesenchyme transition (EMT). Inhibiting the enzymatic activities of NUDT5 prevents oncosphere formation and precludes the activation of cancer driver genes. These findings highlight NUDT5 as an upstream regulator of tumour drivers and may provide a biomarker for cancer stratification, as well as a novel target for drug discovery for combinatorial drug regimens for the treatment of aggressive cancer types and metastasis.

22 February 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JSJos Smits
Jos Smits
JQJieqiong Qu
Jieqiong Qu
FPFelicitas Pardow
Felicitas Pardow
NBNoa J.M. van Den Brink
Noa J.M. van Den Brink
DRDiana Rodijk-Olthuis
Diana Rodijk-Olthuis
EBEllen H. van den Bogaard
Ellen H. van den Bogaard

8 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJos Smits
Jos Smits
JQJieqiong Qu
Jieqiong Qu
FPFelicitas Pardow
Felicitas Pardow
NBNoa J.M. van Den Brink
Noa J.M. van Den Brink
DRDiana Rodijk-Olthuis
Diana Rodijk-Olthuis
EBEllen H. van den Bogaard
Ellen H. van den Bogaard
The aryl hydrocarbon receptor (AHR) is an evolutionary conserved environmental sensor identified as indispensable regulator of epithelial homeostasis and barrier organ function. Molecular signaling cascade and target genes upon AHR activation and their contribution to cell and tissue function are however not fully understood. Multi-omics analyses using human skin keratinocytes revealed that, upon ligand activation, AHR binds open chromatin to induce expression of transcription factors (TFs), e.g., Transcription Factor AP-2α (TFAP2A), as a swift response to environmental stimuli. The terminal differentiation program including upregulation of barrier genes, filaggrin and keratins, was mediated by TFAP2A as a secondary response to AHR activation. The role of AHR-TFAP2A axis in controlling keratinocyte terminal differentiation for proper barrier formation was further confirmed using CRISPR/Cas9 in human epidermal equivalents. Overall, the study provides novel insights into the molecular mechanism behind AHR-mediated barrier function and potential novel targets for the treatment of skin barrier diseases.

23 September 2022
Verified
Conference Paper
Closed access
FPFelicitas Pardow
Felicitas Pardow
GRGijs Rikken
Gijs Rikken
DRDiana Rodijk-Olthuis
Diana Rodijk-Olthuis
IVIvonne van Vlijmen-Willems
Ivonne van Vlijmen-Willems
HZHuiqing (Jo) Zhou
Huiqing (Jo) Zhou
EBEllen H. van den Bogaard
Ellen H. van den Bogaard
Atopic dermatitis (AD) is a chronic inflammatory skin disease in which patients suffer from red, itching skin lesions. Current therapeutics targe | POSTER